Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Induction Therapy with Everolimus in Combination with DHAP (Dexamethasone, High-Dose AraC, Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Randomized, Placebo-Controlled Phase I/II Trial (HD-R3i)

Bastian von Tresckow, MD, Andreas Hüttmann, MD, Vladan Vucinic, MD, Horst Mueller, PhD, Annette Plütschow, Andreas Viardot, MD, Max S. Topp, Carsten Kobe, MD, Boris Böll, MD, Dennis A. Eichenauer, Stephanie Sasse, MD, Heinz Haverkamp, Michael Fuchs, Andreas Engert, MD, Peter Borchmann, MD

Blood (2018) 132 (Supplement 1): 2912.

https://doi.org/10.1182/blood-2018-99-117291

Published: 2018

Journal Articles

Beacoppescalated Followed By Radiotherapy of Initial Bulk or Residual Disease in Advanced Stage Hodgkin Lymphoma: Long-Term Follow up of the HD9 and HD12 Trials of the German Hodgkin Study Group

Stefanie Kreissl, MD, Bastian von Tresckow, MD, Helen Goergen, PhD, Heinz Haverkamp, Stephanie Sasse, MD, Volker Diehl, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2016) 128 (22): 923.

https://doi.org/10.1182/blood.V128.22.923.923

Published: 2016

Journal Articles

Thrombosis in Hodgkin Lymphoma Patients: Incidence, Time Points, Risk Factors and Impact of Stage and Treatment

Sven Borchmann, MD, Ida Hude, MD, Horst Müller, PhD, Heinz Haverkamp, Carolin Bürkle, MD, Michael Fuchs, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2016) 128 (22): 4151.

https://doi.org/10.1182/blood.V128.22.4151.4151

Published: 2016

Journal Articles

Targeted Beacopp Variants in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study

Peter Borchmann, MD, Dennis A. Eichenauer, MD, Annette Pluetschow, Heinz Haverkamp, Stefanie Kreissl, MD, Michael Fuchs, Martin Soekler, Johannes C. Hellmuth, MD, Julia Meissner, MD, Stephan Mathas, Karolin Behringer, MD, Markus Dietlein, Carsten Kobe, Volker Diehl, MD, Andreas Engert

Blood (2015) 126 (23): 580.

https://doi.org/10.1182/blood.V126.23.580.580

Published: 2015

Journal Articles

A Phase I Study of Everolimus in Combination with Time-Intensified DHAP (Dexamethasone, High-Dose AraC [Cytarabine], Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

Bastian von Tresckow, MD, Annette Pluetschow, Heinz Haverkamp, Vladan Vucinic, MD, Andreas Rank, MD, Max S. Topp, MD, Michaela Feuring-Buske, MD, Carsten Kobe, MD, Georg Kuhnert, MD, Boris Böll, MD, Dennis A. Eichenauer, MD, Stephanie Sasse, MD, Michael Fuchs, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2014) 124 (21): 4433.

https://doi.org/10.1182/blood.V124.21.4433.4433

Published: 2014

Journal Articles

Addition of Rituximab to BEACOPP escalated to Improve the Outcome of Early Interim PET Positive Advanced Stage Hodgkin Lymphoma Patients: Second Planned Interim Analysis of the HD18 Study.

Peter Borchmann, MD, Heinz Haverkamp, Andreas Lohri, MD, Stefanie Kreissl, MD, Richard Greil, MD, Jana Markova, MD, Michaela Feuring-Buske, MD, Julia Meissner, MD, Ulrich Dührsen, Nicole Engel, MD, Ulrich Keller, MD, Georg Maschmeyer, MD, Markus Dietlein, MD, Carsten Kobe, MD, Michael Fuchs, MD, Volker Diehl, MD, Andreas Engert, MD

Blood (2014) 124 (21): 500.

https://doi.org/10.1182/blood.V124.21.500.500

Published: 2014

Journal Articles

Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group

Dennis A. Eichenauer, Indra Thielen, Heinz Haverkamp, Jeremy Franklin, Karolin Behringer, Teresa Halbsguth, Beate Klimm, Volker Diehl, Stephanie Sasse, Achim Rothe, Michael Fuchs, Boris Böll, Bastian von Tresckow, Peter Borchmann, Andreas Engert

Blood (2014) 123 (11): 1658–1664.

https://doi.org/10.1182/blood-2013-07-512657

Published: 2014

Includes: Supplemental data

Journal Articles

Impact Of Dose Reduction Of Bleomycin and Vincristine In Patients With Advanced Hodgkin Lymphoma Treated With Beacopp: A Comprehensive Analysis Of The German Hodgkin Study Group (GHSG) HD12 and HD15 Trials

Bastian von Tresckow, MD, Heinz Haverkamp, Boris Böll, MD, Dennis A. Eichenauer, MD, Stephanie Sasse, MD, Michael Fuchs, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2013) 122 (21): 637.

https://doi.org/10.1182/blood.V122.21.637.637

Published: 2013

Journal Articles

Relative Reduction of Residual Tumor Improves Outcome Prediction of PET After Effective Chemotherapy for Patients with Advanced Stage Hodgkin Lymphoma

Andreas Engert, MD, Carsten Kobe, MD, Heinz Haverkamp, Georg Kuhnert, Jana Markova, MD, Andreas Lohri, MD, Susanne Klutmann, MD, Holger Amthauer, MD, Volker Diehl, MD, Peter Borchmann, MD, Markus Dietlein, MD

Blood (2012) 120 (21): 3684.

https://doi.org/10.1182/blood.V120.21.3684.3684

Published: 2012

Journal Articles

First Line Treatment of Advanced Stage Hodgkin Lymphoma with Six Cycles of BEACOPP escalated Results in Superior Overall Survival Compared to ABVD: Results of a Network Meta-Analysis Including 10,011 Patients

Peter Borchmann, MD, Sven Trelle, Michaela Rancea, Heinz Haverkamp, Volker Diehl, MD, Nicole Skoetz, MD, Andreas Engert, MD

Blood (2012) 120 (21): 551.

https://doi.org/10.1182/blood.V120.21.551.551

Published: 2012

Journal Articles

Reduced Intensity of Chemotherapy and PET-Guided Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma: The GHSG HD15 Final Results

Andreas Engert, MD, Heinz Haverkamp, Carsten Kobe, MD, Jana Markova, MD, Christoph Renner, MD, Anthony D. Ho, MD, PhD, Josée Zijlstra, MD, Zdenek Král, MD, Harald Stein, MD, Hans Theodor Eich, MD, Rolf-Peter Müller, MD, Markus Dietlein, MD, Peter Borchmann, MD, Volker Diehl, MD

Blood (2011) 118 (21): 589.

https://doi.org/10.1182/blood.V118.21.589.589

Published: 2011

Journal Articles

Assessment of Residual Bulky Tumor Using FDG-PET In Patients with Advanced-Stage Hodgkin Lymphoma After Completion of Chemotherapy: Final Report of the GHSG HD15 Trial

Andreas Engert, MD, Carsten Kobe, Jana Markova, Heinz Haverkamp, Peter Borchmann, Felicitas Hitz, Josee Zijlstra, Hans Eich, Rolf-Peter Mueller, Markus Dietlein, Volker Diehl

Blood (2010) 116 (21): 764.

https://doi.org/10.1182/blood.V116.21.764.764

Published: 2010

Journal Articles

Secondary MDS/AML In Hodgkin Lymphoma Patients Treated within German Hodgkin Study Group (GHSG) Clinical Trials After Introduction of the BEACOPP Protocol

Dennis A. Eichenauer, Heinz Haverkamp, Karolin Behringer, Teresa Halbsguth, MD, Michael Fuchs, Volker Diehl, Peter Borchmann, Andreas Engert

Blood (2010) 116 (21): 2682.

https://doi.org/10.1182/blood.V116.21.2682.2682

Published: 2010

Journal Articles

Hodgkin Lymphoma in Adolescents Treated with Adult Protocols: An Analysis From the German Hodgkin Study Group (GHSG).

Dennis A. Eichenauer, Henning Bredenfeld, Jeremy Franklin, Heinz Haverkamp, Horst Mueller, Hans T. Eich, Rolf-Peter Mueller, Michael Fuchs, Peter Borchmann, Volker Diehl, Andreas Engert

Blood (2009) 114 (22): 719.

https://doi.org/10.1182/blood.V114.22.719.719

Published: 2009

Journal Articles

Eight Cycles of BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated Followed by 4 Cycles of BEACOPP Baseline with Our without Radiotherapy in Patients in Advanced Stage Hodgkin Lymphoma (HL): Final Analysis of the Randomised HD12 Trial of the German Hodgkin Study Group (GHSG).

Volker Diehl, Heinz Haverkamp, Rolf Peter Mueller, Hans Theodor Eich, Hans Konrad Mueller-Hermelink, Thomas Cerny, Jana Markova, Anthony Ho, Lothar Kanz, Richard Greil, Wolfgang Hiddemann, Andreas Engert

Blood (2008) 112 (11): 1558.

https://doi.org/10.1182/blood.V112.11.1558.1558

Published: 2008

Journal Articles

A Prospectively Randomized Placebo-Controlled Trial of Epoetin-α in Patients with Advanced-Stage Hodgkin Lymphoma: Final Analysis of the GHSG HD15-EPO Trial

Andreas Engert, Peter Borchmann, Michael Fuchs, Andreas Josting, Heinz Haverkamp, Volker Diehl

Blood (2008) 112 (11): 2598.

https://doi.org/10.1182/blood.V112.11.2598.2598

Published: 2008

Journal Articles

FDG-PET for Assessment of Residual Tissue after Completion of Chemotherapy in Hodgkin Lymphoma - Report on the 2 nd Interim Analysis of the PET Investigation in the Trial HD15 of the GHSG.

Volker Diehl, Carsten Kobe, Heinz Haverkamp, Markus Dietlein, Andreas Engert

Blood (2007) 110 (11): 212.

https://doi.org/10.1182/blood.V110.11.212.212

Published: 2007

Journal Articles

Identification of Prognostic Factors in Early Unfavorable Stage Hodgkin’s Lymphoma (HL): An Individual Patient Data Meta-Analysis.

Julia Bohlius, Heinz Haverkamp, Volker Diehl, Houchingue Eghbali, Christopher Ferme, Jeremy Franklin, Beate Pfistner, Petra Schiller, John Raemaekers, Andreas Engert, Michel Henry-Amar

Blood (2006) 108 (11): 2473.

https://doi.org/10.1182/blood.V108.11.2473.2473

Published: 2006

Journal Articles

Leucopenia during Treatment Is a Good Prognostic Risk Factor for Patients Undergoing Chemotherapy for Hodgkin’s Lymphoma: An Analysis of the German Hodgkin Study Group (GHSG).

Beate Klimm, Thorsten Reineke, Heinz Haverkamp, Hans T. Eich, Karolin Behringer, Andreas Josting, Beate Pfistner, Volker Diehl, Andreas Engert

Blood (2005) 106 (11): 2674.

https://doi.org/10.1182/blood.V106.11.2674.2674

Published: 2005

Journal Articles

Identification of Prognostic Factors in Patients with Early Stage Unfavorable Hodgkin’s Lymphoma: An Individual Patient Data Meta-Analysis.

Julia Bohlius, MD, MScPH, Heinz Haverkamp, MSc, Volker Diehl, MD, Houchingue Eghbali, MD, Jeremy Franklin, MSc, Beate Pfistner, MSc, John Raemaekers, MD, PhD, Andreas Engert, MD, Michel Henry-Amar, MD, PhD

Blood (2005) 106 (11): 5577.

https://doi.org/10.1182/blood.V106.11.5577.5577

Published: 2005

NARROW

Induction Therapy with Everolimus in Combination with DHAP (Dexamethasone, High-Dose AraC, Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Randomized, Placebo-Controlled Phase I/II Trial (HD-R3i)

Beacoppescalated Followed By Radiotherapy of Initial Bulk or Residual Disease in Advanced Stage Hodgkin Lymphoma: Long-Term Follow up of the HD9 and HD12 Trials of the German Hodgkin Study Group

Thrombosis in Hodgkin Lymphoma Patients: Incidence, Time Points, Risk Factors and Impact of Stage and Treatment

Targeted Beacopp Variants in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study

A Phase I Study of Everolimus in Combination with Time-Intensified DHAP (Dexamethasone, High-Dose AraC [Cytarabine], Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

Addition of Rituximab to BEACOPP escalated to Improve the Outcome of Early Interim PET Positive Advanced Stage Hodgkin Lymphoma Patients: Second Planned Interim Analysis of the HD18 Study.

Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group

Impact Of Dose Reduction Of Bleomycin and Vincristine In Patients With Advanced Hodgkin Lymphoma Treated With Beacopp: A Comprehensive Analysis Of The German Hodgkin Study Group (GHSG) HD12 and HD15 Trials

Relative Reduction of Residual Tumor Improves Outcome Prediction of PET After Effective Chemotherapy for Patients with Advanced Stage Hodgkin Lymphoma

First Line Treatment of Advanced Stage Hodgkin Lymphoma with Six Cycles of BEACOPP escalated Results in Superior Overall Survival Compared to ABVD: Results of a Network Meta-Analysis Including 10,011 Patients

Reduced Intensity of Chemotherapy and PET-Guided Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma: The GHSG HD15 Final Results

Assessment of Residual Bulky Tumor Using FDG-PET In Patients with Advanced-Stage Hodgkin Lymphoma After Completion of Chemotherapy: Final Report of the GHSG HD15 Trial

Secondary MDS/AML In Hodgkin Lymphoma Patients Treated within German Hodgkin Study Group (GHSG) Clinical Trials After Introduction of the BEACOPP Protocol

Hodgkin Lymphoma in Adolescents Treated with Adult Protocols: An Analysis From the German Hodgkin Study Group (GHSG).

Eight Cycles of BEACOPP Escalated Compared with 4 Cycles of BEACOPP Escalated Followed by 4 Cycles of BEACOPP Baseline with Our without Radiotherapy in Patients in Advanced Stage Hodgkin Lymphoma (HL): Final Analysis of the Randomised HD12 Trial of the German Hodgkin Study Group (GHSG).

A Prospectively Randomized Placebo-Controlled Trial of Epoetin-α in Patients with Advanced-Stage Hodgkin Lymphoma: Final Analysis of the GHSG HD15-EPO Trial

FDG-PET for Assessment of Residual Tissue after Completion of Chemotherapy in Hodgkin Lymphoma - Report on the 2 nd Interim Analysis of the PET Investigation in the Trial HD15 of the GHSG.

Identification of Prognostic Factors in Early Unfavorable Stage Hodgkin’s Lymphoma (HL): An Individual Patient Data Meta-Analysis.

Leucopenia during Treatment Is a Good Prognostic Risk Factor for Patients Undergoing Chemotherapy for Hodgkin’s Lymphoma: An Analysis of the German Hodgkin Study Group (GHSG).

Identification of Prognostic Factors in Patients with Early Stage Unfavorable Hodgkin’s Lymphoma: An Individual Patient Data Meta-Analysis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only